Pipeline

R&D nke Sorrento lekwasịrị anya na ịnya ụgbọ ala ọhụrụ na COVID-19, ọgwụgwọ ọrịa kansa, njikwa mgbu zuru oke na ọrịa autoimmune.

Mmemme igodo Ntu Mgbochi Na-adọ 1 Oge Abụọ Nkeji III/Pivotal Nkwado FDA
Mmemme COVID-19  

COVISTIX™ (nchọpụta nchọpụta) Nnwale Antigen ngwa ngwa

*

Ikike iji ihe mberede (EUA) na Mexico (COFEPRIS), Brazil (ANVISA), na CE akara na Europe.

COVIMARK™ (nchọpụta nchọpụta) Nnwale Antigen ngwa ngwa

*

Ngwa etinyere na US na Canada maka ikike iji ihe mberede (EUA)

COVISHIELD™ (ọgwụgwọ) Antibody na-anọpụ iche (IN) n'ime ndị ọrịa na-arịa ọrịa na ndị ọrịa nọ n'ụlọ ọgwụ

40%*

COVISHIELD™ (ọgwụgwọ) Neutralizing Antibody (IV) n'ime ndị ọrịa na-arịa ọrịa na ndị ọrịa nọ n'ụlọ ọgwụ

20%*

FUJOVEE (Abivertinib) COVID-19 siri ike na ndị ọrịa ICU

82%*

Ọnwụnwa dị mkpa na-echere mkpochapụ FDA

OQORY™ (COVI-MSC) ARDS n'ihi COVID-19 n'ime ndị ọrịa ICU

82%*

Ọnwụnwa dị mkpa na Brazil

Mpro Ihe mgbochi (ọgwụ ọnụ) Ọrịa mgbochi

40%*

Omicron mRNA ogwu Vaccine

20%*

Mmemme igodo Ntu Mgbochi Na-adọ 1 Oge Abụọ Nkeji III/Pivotal Nkwado FDA
immunotherapy  

FUJOVEE (Abivertinib) NSCLC

82%*

FUJOVEE (Abivertinib) B cell Lymphomas

60.2%*

FUJOVEE (Abivertinib) Prostate

20%*

FUJOVEE (Abivertinib) Lupus

20%*

FUJOVEE (Abivertinib) MS

20%*

FUJOVEE (Abivertinib) GvHD

20%*

PD-L1 (Socazolimab)* SCLC

82%*

* Na mmekorita ya na Lee's Pharm na China

PD-L1 (STI-3031)** Ọrịa Cervical

82%*

** Na US yana mmekorita ya na ImmuneOncia na Korea

CD47 Tumor siri ike

40%*

CD38 DAR-T multiple Myeloma

40%*

CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, na esophageal

40%*

TROP2 ADC* Tumor siri ike

40%*

* Na China

Seprehvec™ oncolytic nje Tumor siri ike; CNS Tumor

40%*

Ọnụ ego nke BCMA ADC Tumor Liquid

20%*

Bevacizumab-ADNAB™ Ọrịa kansa Endometrial

40%*

Na mmekorita ya na Mayo Clinic

Bevacizumab-ADNAB™ Ọrịa Ovarian

40%*

Na mmekorita ya na Mayo Clinic

Rituximab-ADNAB™ B-cell Lymphomas

40%*

Na mmekorita ya na Mayo Clinic
Mmemme igodo Ntu Mgbochi Na-adọ 1 Oge Abụọ Nkeji III/Pivotal Nkwado FDA
Pain  

ZTlido™ 1.8%
Neuralgia Postherpetic - PHN

99.8%*

SP-102 (SEMDEXA) Lumbar Radicular/Sciatica mgbu

82%*

SP-103 (Sistemụ Topical Lidocaine 5.4%) Nnukwu Mgbu mgbu

20%*

SP-104 (Naltrexone obere dose gbawara egbu oge) Fibromyalgia

20%*

RTX (resiferatoxin)
Epidural injection
Ihe mgbu na-adịghị agwụ agwụ na ọrịa kansa dị elu

60.3%*

Nhọpụta nwa mgbei

RTX (resiferatoxin)
Ụzọ intra-articular
OA Mgbu OA Na-agafeghị agafe ruo Dị Ike

60.2%*

Mmemme igodo Ntu Mgbochi Na-adọ 1 Oge Abụọ Nkeji III/Pivotal Nkwado FDA
Nnyefe Lymphatic  

Sofusa® mgbochi TNF Autoimmune (RA)

40%*

Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL)

40%*

Sofusa® mgbochi CTLA-4 Melanoma

40%*

Na mmekorita ya na Mayo Clinic
Mmemme COVID-19
Mmemme igodo (Ngosipụta) adọ
COVISTIX™ (nchọpụta nchọpụta) FDA EUA
COVIMARK™ (nchọpụta nchọpụta) FDA EUA
COVISHIELD™ (ọgwụgwọ) PH I
COVISHIELD™ (ọgwụgwọ) Mgbochi
FUJOVEE (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
Mpro Inhibitor (mkpụrụ ọgwụ ọnụ) (mgbochi nje) Ph I
Omicron mRNA ogwu (ọgwụ mgbochi) Mgbochi
immunotherapy
Mmemme igodo (Ngosipụta) adọ
FUJOVEE™ (Abivertinib) (NSCLC) Ph III
FUJOVEE™ (Abivertinib) Lymphoma nke mkpụrụ ndụ B cell Ph II
FUJOVEE™ (Abivertinib) (Prostate) Mgbochi
FUJOVEE™ (Abivertinib) (Lupus) Mgbochi
FUJOVEE™ (Abivertinib) (MS) Mgbochi
FUJOVEE™ (Abivertinib) (GvHD) Mgbochi
PD-L1 (Socazolimab)*(SCLC) Ph III
PD-L1 (STI-3031)** (Cervical Cancer) Ph III
CD47 Tumor siri ike Ph I
CD38 DAR-T (Otu Myeloma) Ph I
CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, na esophageal) Ph I
TROP2 ADC* Tumor siri ike Ph I
Seprehvec™ oncolytic nje Tumor siri ike (CNS Tumors) PH I
Ọnụ ego nke BCMA ADC ( Tumor Liquid) Mgbochi
Bevacizumab-ADNAB™ (ọrịa cancer endometrial) Ph I
Bevacizumab-ADNAB™ (ọrịa cancer ovarian) Ph I
Rituximab-ADNAB™ (B-cell Lymphomas) Ph I
Pain
Mmemme igodo (Ngosipụta) adọ
ZTlido™ 1.8% (Postherpetic Neuralgia - PHN) Nkwado FDA
SP-102 (SEMDEXA) Ph III
SP-103 (Sistemụ Topical Lidocaine 5.4%) Mgbochi
SP-104 (Naltrexone obere dose gbawara egbu oge) Mgbochi
RTX (resiniferatoxin) ogwu ogwu ogwu (Mgbu na-adịghị agwụ agwụ na ọrịa kansa dị elu) Ph II
RTX (resiniferatoxin) Ụzọ intra-articular (Ọ dị oke oke ruo nke ukwuu mgbu ikpere OA) Ph II
Nnyefe Lymphatic
Mmemme igodo (Ngosipụta) Oge Abụọ
Sofusa® mgbochi TNF (Akụkụ nke onwe RA) Ph I
Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL) Ph I
Sofusa® mgbochi CTLA-4 (Melanoma) Ph I